The Current Use of Drug-Eluting Balloons and Stents in Peripheral Arterial Disease: An Online Survey by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).


Journal

Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 03 08 2023
accepted: 07 09 2023
medline: 5 12 2023
pubmed: 28 9 2023
entrez: 27 9 2023
Statut: ppublish

Résumé

To assess the current use of drug-eluting devices for peripheral arterial disease (PAD) among interventional radiologists following the controversy caused by the 2018 meta-analysis suggesting an increased mortality risk for paclitaxel-eluting devices. An anonymous survey was sent to 7035 CIRSE members via email; only complete responses were included and statistically analysed. Three hundred and seven members (4.4%) completed the survey. Among these, 95.8% indicated that they personally perform peripheral vascular procedures. Thirty-eight percentage of respondents did not see any change of practice since 2018, while 47% reported that the use of drug-eluting devices decreased; for 13%, the use stopped altogether, while it increased in 3% of responses. 45.6% of respondents also felt the impact of the controversy in terms of pricing, availability or directives from hospital administration. A large majority of respondents (83.7%) who perform peripheral vascular procedures consider the use of these devices as safe, 12.9% were undecided and 3.4% did not consider them as safe. Among the respondents who do not perform endovascular procedures, 77% considered these devices as safe and 23% were undecided. Although the 2018 meta-analysis had a disruptive impact on the use of drug-eluting devices in PAD, with the increasing body of evidence available, a majority of respondents continue to believe in the safety of these devices for use in femoropopliteal disease.

Identifiants

pubmed: 37759088
doi: 10.1007/s00270-023-03562-3
pii: 10.1007/s00270-023-03562-3
pmc: PMC10695858
doi:

Substances chimiques

Paclitaxel P88XT4IS4D
Coated Materials, Biocompatible 0

Types de publication

Meta-Analysis Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1743-1747

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

J Am Heart Assoc. 2018 Dec 18;7(24):e011245
pubmed: 30561254
Cardiovasc Intervent Radiol. 2020 Dec;43(12):1881-1888
pubmed: 32725411
Cardiovasc Intervent Radiol. 2023 Aug;46(8):977-980
pubmed: 37436438

Auteurs

Robert A Morgan (RA)

St George's University of London, London, UK. rmorgan@sgul.ac.uk.

Stefan Müller-Hülsbeck (S)

Academic Hospital Christian-Albrechts-University Kiel, Kiel, Germany.

Fabrizio Fanelli (F)

Vascular and Interventional Radiology Department, "Careggi" University Hospital - University of Florence, Florence, Italy.

Patrick Haage (P)

Helios University Hospital, University Witten/Herdecke, Wuppertal, Germany.

Mohamad Hamady (M)

Imperial College, St Mary's Campus, London, UK.

Romaric Loffroy (R)

Department of Diagnostic and Interventional Radiology, University of Burgundy, Dijon, France.

Gerard O'Sullivan (G)

University Hospital Galway, Galway, Ireland.

Florian Wolf (F)

Division of Cardiovascular and Interventional Radiology, Medical University of Vienna, Vienna, Austria.

Birgit Slijepčević (B)

CIRSE Central Office, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH